Lin Wei Wu
Sun Yat-sen University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lin Wei Wu.
Journal of Digestive Diseases | 2013
An Bin Hu; Lin Wei Wu; Qiang Tai; Xiao Feng Zhu; Xiao Shun He
To evaluate the safety and efficacy of steroid‐minimization therapy in liver transplantation (LT) recipients with hepatitis B virus‐related diseases in China.
Hepatobiliary & Pancreatic Diseases International | 2014
Ming Han; Zhi Yong Guo; Qiang Zhao; Xiaoping Wang; Xiao Peng Yuan; Xing Yuan Jiao; Chun Hua Yang; Dongping Wang; Wei Qiang Ju; Lin Wei Wu; An Bin Hu; Qiang Tai; Yi Ma; Xiao Feng Zhu; Xiao Shun He
BACKGROUND In 2011, a pilot program for deceased organ donation was initiated in China. We describe the first successful series of liver transplants in the pilot program. METHODS From July 2011 to August 2012, our center performed 26 liver transplants from a pool of 29 deceased donors. All organ donation and allograft procurement were conducted according to the national protocol. The clinical data of donors and recipients were collected and summarized retrospectively. RESULTS Among the 29 donors, 24 were China Category II donors (organ donation after cardiac death), and five were China Category III donors (organ donation after brain death followed by cardiac death). The recipients were mainly the patients with hepatocellular carcinoma. The one-year patient survival rate was 80.8% with a median follow-up of 422 (2-696) days. Among the five mortalities during the follow-up, three died of tumor recurrence. In terms of post-transplant complications, 9 recipients (34.6%) experienced early allograft dysfunction, 1 (3.8%) had non-anastomotic biliary stricture, and 1 (3.8%) was complicated with hepatic arterial thrombosis. None of these complications resulted in patient death. Notably, primary non-function was not observed in any of the grafts. CONCLUSION With careful donor selection, liver transplant from deceased donors can be performed safely and plays a critical role in overcoming the extreme organ shortage in China.
Hepatobiliary & Pancreatic Diseases International | 2012
Lin Wei Wu; Zhi Yong Guo; Qiang Tai; Wei Qiang Ju; Dongping Wang; An Bin Hu; Xiao Feng Zhu; Xiao Shun He
BACKGROUND Steroids have been the mainstay of immunosuppressive regimen in liver transplantation. However, the use of steroids is associated with various post-transplant complications. This study evaluated the efficacy and safety of reduced immunosuppressive regimen with steroids (steroid elimination within 24 hours post-transplant) in a cohort of Chinese liver transplant recipients. METHODS Seventy-six patients in line with the selection criteria were enrolled in this prospective study. All patients received anti-IL-2 receptor antibody induction and tacrolimus-based maintenance therapy. The recipients were divided into two groups according to the duration of steroid use: 40 transplant in a 3-month withdrawal group and the remaining 36 in a 24-hour elimination group. Recipient survival, post-operative infections, biopsy-proven acute rejection and steroid-resistant acute rejection, non-healing wound, recurrence of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC), de novo diabetes, hyperlipidemia and hypertension were assessed in the two groups. RESULTS There was no significant difference in patient survival, incidence of acute rejection episodes and hyperlipidemia, and recurrence of HBV and HCC between the two groups. However, the incidence rates of post-transplant infection, non-healing wound, de novo diabetes and hypertension were significantly lower in the 24-hour elimination group than in the 3-month withdrawal group (all P values <0.05). CONCLUSION Under anti-IL-2 receptor antibody induction and tacrolimus-based maintainance, steroid elimination within 24 hours post-transplant is associated with reduced steroid-related complications without increasing the risk of rejection.
Oncotarget | 2017
Shun Jun Fu; Fei Ji; Ming Han; Mao Gen Chen; Xiaoping Wang; Wei Qiang Ju; Qiang Zhao; Lin Wei Wu; Qing Qi Ren; Zhi Yong Guo; Dongping Wang; Xiao Feng Zhu; Yi Ma; Xiao Shun He
Objectives Elevated plasma fibrinogen (Fib) correlated with patients prognosis in several solid tumors. However, few studies have illuminated the relationship between preoperative Fib and prognosis of HCC after liver transplantation. We aimed to clarify the prognostic value of Fib and whether the prognostic accuracy can be enhanced by the combination of Fib and neutrophil–lymphocyte ratio (NLR). Results Fib was correlated with Child-pugh stage, alpha-fetoprotein (AFP), size of largest tumor, macro- and micro-vascular invasion. Univariate analysis showed preoperative Fib, AFP, NLR, size of largest tumor, tumor number, macro- and micro- vascular invasion were significantly associated with disease-free survival (DFS) and overall survival (OS) in HCC patients with liver transplantation. After multivariate analysis, only Fib and macro-vascular invasion were independently correlated with DFS and OS. Survival analysis showed that preoperative Fib > 2.345 g/L predicted poor prognosis of patients HCC after liver transplantation. Preoperative Fib showed prognostic value in various subgroups of HCC. Furthermore, the predictive range was expanded by the combination of Fib and NLR. Materials and Methods Data were collected retrospectively from 130 HCC patients who underwent liver transplantation. Preoperative Fib, NLR and clinicopathologic variables were analyzed. The survival analysis was performed by the Kaplan-Meier method, and compared by the log-rank test. Univariate and multivariate analyses were performed to identify the prognostic factors for DFS and OS. Conclusions Preoperative Fib is an independent effective predictor of prognosis for HCC patients, higher levels of Fib predict poorer outcomes and the combination of Fib and NLR enlarges the prognostic accuracy of testing.
World Journal of Gastroenterology | 2008
Zhi Yong Guo; Xiao Shun He; Lin Wei Wu; Xiao Feng Zhu; Wei Qiang Ju; Dongping Wang; Shen You; Yi Ma; Guo Dong Wang; Jie Fu Huang
Experimental and Clinical Transplantation | 2012
Wei Qiang Ju; Zhi Yong Guo; Xiaoting Ling; Xiao Shun He; Lin Wei Wu; Qiang Tai; An Bin Hu; Ming Han; Xiao Feng Zhu
Hepatobiliary & Pancreatic Diseases International | 2003
Xiao Shun He; Yi Ma; Lin Wei Wu; Wei Qiang Ju; Chen Gh; Hu Rd; Jie Fu Huang
Experimental and Clinical Transplantation | 2012
Wei Qiang Ju; Zhi Yong Guo; Wen Hua Liang; Lin Wei Wu; Qiang Tai; An Bin Hu; Ming Han; Xiao Feng Zhu; Xiaoshun He
Chinese journal of surgery | 2008
You S; Xiao Shun He; An Bin Hu; Xiong J; Lin Wei Wu; Dongping Wang; Guo Dong Wang; Yi Ma; Wei Qiang Ju; Jie Fu Huang
Chinese journal of surgery | 2008
An Bin Hu; Xiao Shun He; Zhi peng Wu; Xiao Feng Zhu; Yi Ma; Dongping Wang; Guo Dong Wang; Qiang Tai; Wei Qiang Ju; Lin Wei Wu; Jie Fu Huang